CTOs on the Move

Tonix Pharmaceuticals

www.tonixpharma.com

 
Tonix Pharmaceuticals develops first-in-class medicines for common disorders of the central nervous system, including fibromyalgia, post-traumatic stress disorder, and episodic tension-type headache. These disorders are characterized by chronic disability, inadequate treatment options, high utilization of healthcare services, and significant economic burden. Tonix`s lead product candidate, TNX-102 SLAttribution (cyclobenzaprine HCl sublingual tablet), is designed to be a fundamental advance in sleep hygiene and pain management for patients suffering from fibromyalgia and post-traumatic stress disorder (PTSD). Product candidate TNX-201Attribution ((R)-isometheptene mucate) is in development for episodic tension-type headache, the most common form of headache.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Tonix Pharmaceuticals raised $40M on 01/13/2021
Tonix Pharmaceuticals raised $70M on 02/08/2021

Similar Companies

Reflex Photonics

Reflex Photonics Inc. is a Sherbrooke, QC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

HealthTell

HealthTell is committed to empowering the next generation of diagnostics and therapeutics for complex immune-mediated diseases such as cancer, autoimmune disorders, and infectious diseases. Based on robust proprietary technology, HealthTell is developing the first and only diagnostic platform capable of assessing an individual`s immune system response to specific diseases. Applicable to a broad range of therapeutic areas, HealthTell is empowering physicians and patients to proactively manage health and make more informed decisions.

Beta Bionics

Beta Bionics is proud to be a Massachusetts public benefit corporation.

Network Biosystems

Network Biosystems, Inc. is a Woburn, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Frequency Therapeutics

Frequency Therapeutics develops small molecule drugs that activate progenitor cells within the body to restore healthy tissue. Through the controlled activation of progenitor cells, Frequency enables disease modification without the complexity of genetic engineering. Our lead program re-creates sensory cells in the inner ear to treat chronic noise induced hearing loss, which affects over 30 million people in the U.S. alone.